Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow
Reuters
Published Apr 24, 2015 07:39AM ET
Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow
(Reuters) - Biogen (NASDAQ:BIIB) Inc posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis (MS) drug Tecfidera showed signs of slowing growth, sending the company's shares down 3 percent in premarket trading on Friday.
The drug's sales have shown little sign of slowing after falling short of analysts' estimates for the first time in the third quarter of 2014. Sales of Tecfidera beat the average analyst estimate by about $36 million last quarter.
Tecfidera raked in sales of $824.9 million in the first quarter ended March 31, compared with $506 million a year earlier, but missed consensus projections of about $931 million, according to Deutsche Bank (XETRA:DBKGn).
Sales of the drug fell 10 percent compared with the fourth quarter of 2014, the company said.
We saw moderating patient growth of Tecfidera in the United States and Germany, Chief Executive George Scangos said in a statement.
Net income attributable to Biogen rose to $822.5 million, or $3.49 per share in the first quarter, from $480 million, or $2.02 per share, a year earlier.
Excluding items, the company earned $3.82 per share, well below the average analyst estimate $3.91 per share, according to Thomson Reuters I/B/E/S.
Revenue rose about 20 percent to $2.55 billion, missing Wall Street's projections of $2.66 billion.
The Cambridge, Massachusetts-based company's stock was down about 3 percent at $416.55 before the bell.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.